Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms?

Cancers (Basel) · 2021 · PMC8038369 · PMID 33916707

Europe PMC DOI

hedged sentence

0.1690

closest p · 3.4× alpha

0.1690

boldest claim

The sentences

did not reach statistical significancep = 0.169not close (p > 0.1)

The median PFS per investigator assessment was 17.2 months for the axitinib–octreotide arm versus 12.3 months for the placebo–octreotide arm, but this difference did not reach statistical significance (HR 0.816, p = 0.169).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.